(Q37716581)

22 August 2017

1 reference

title

HDL metabolism and activity in chronic kidney disease (English)

1 reference

22 August 2017

1

Nosratola D Vaziri

1 reference

22 August 2017

Mohamad Navab

2

1 reference

22 August 2017

Alan M Fogelman

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

23 March 2010

1 reference

Nature Reviews Nephrology

22 August 2017

published in

1 reference

22 August 2017

volume

6

1 reference

22 August 2017

issue

5

1 reference

22 August 2017

page(s)

287-296

1 reference

Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Upregulation of acyl-CoA: cholesterol acyltransferase in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

HDL and the inflammatory response induced by LDL-derived oxidized phospholipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Experimental glomerulopathy alters renal cortical cholesterol, SR-B1, ABCA1, and HMG CoA reductase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Acute tubular injury causes dysregulation of cellular cholesterol transport proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

PPARalpha and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Niacin improves renal lipid metabolism and slows progression in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Association of kidney function with mortality in patients with chronic kidney disease not yet on dialysis: a historical prospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Why is chronic kidney disease the "spoiler" for cardiovascular outcomes?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Inflammation in end-stage renal disease: sources, consequences, and therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Oxidative stress in uremia: nature, mechanisms, and potential consequences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Down-regulation of VLDL receptor expression in chronic experimental renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Protein restriction and AST-120 improve lipoprotein lipase and VLDL receptor in focal glomerulosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

The induction of macrophage foam cell formation by chylomicron remnants.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Effects of native and modified low-density lipoproteins on monocyte recruitment in atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Inflammation and atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Macrophage differentiation to foam cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Monocyte recruitment and foam cell formation in atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Oxidized LDL induces enhanced antibody formation and MHC class II-dependent IFN-gamma production in lymphocytes from healthy individuals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Human monocytes/macrophages release TNF-alpha in response to Ox-LDL

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

A role for oxidized phospholipids in atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Formation of dysfunctional high-density lipoprotein by myeloperoxidase.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Serum Myeloperoxidase and Mortality in Maintenance Hemodialysis Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

The double jeopardy of HDL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Oxidized lipids as mediators of coronary heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Endothelial protection by high-density lipoproteins: from bench to bedside

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

High-density lipoprotein metabolism: potential therapeutic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Atheroprotective effects of HDL: beyond reverse cholesterol transport.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Interrelationships among HDL metabolism, aging, and atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Effect of serum subfractions from peritoneal dialysis patients on Hep-G2 cell apolipoprotein A-I and B metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Impaired metabolism of high density lipoprotein in uremic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Role of elevated lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Molecular mechanisms of lipid disorders in nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Identification of scavenger receptor SR-BI as a high density lipoprotein receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Cell surface adenylate kinase activity regulates the F(1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Understanding changes in high density lipoproteins during the acute phase response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

HDL-inflammatory index correlates with poor outcome in hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

The paradox of dysfunctional high-density lipoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Oxidized phospholipids: emerging lipid mediators in pathophysiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Cellular cholesterol substrate pools for adenosine-triphosphate cassette transporter A1-dependent high-density lipoprotein formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Mechanisms of disease: proatherogenic HDL--an evolving field

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Cellular lipid metabolism and the role of lipids in progressive renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Lipotoxicity: when tissues overeat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Atherosclerosis. the road ahead

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Liver X Receptor Signaling Pathways in Cardiovascular Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Reverse cholesterol transport pathway in experimental chronic renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

The role of the kidney in lipid metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

The molecular interactions between filtered proteins and proximal tubular cells in proteinuria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Managing dyslipidemia in chronic kidney disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Lipid management in chronic kidney disease, hemodialysis, and transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

An update on the lipid nephrotoxicity hypothesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Long-Term Stable Expression of Human Apolipoprotein A-I Mediated by Helper-Dependent Adenovirus Gene Transfer Inhibits Atherosclerosis Progression and Remodels Atherosclerotic Plaques in a Mouse Model of Familial Hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Structure and function of HDL mimetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

L-4F, an Apolipoprotein A-1 Mimetic, Dramatically Improves Vasodilation in Hypercholesterolemia and Sickle Cell Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Role of CETP inhibitors in the treatment of dyslipidemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Effects of torcetrapib in patients at high risk for coronary events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Free cholesterol overloading induced smooth muscle cells death and activated both ER- and mitochondrial-dependent death pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.36

Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease

31 March 2020

1 reference

12 December 2020

Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia

1 reference

12 December 2020

Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line.

1 reference

12 December 2020

Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2010.36

1 reference

22 August 2017

1 reference